You are here
Human Microbiome Market - Emerging Trends and Global Future Forecasts by 2025
This report analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia-Pacific, and the Rest of the World.
Browse 91 market data tables and 30 figures spread through 148 pages and in-depth TOC on "Human Microbiome Market"
Early buyers will receive 10% customization on reports.
The human microbiome market is segmented into application, disease, product, and region while the human microbiome research spending market is broadly segmented into product and technology.
The market is expected to reach USD 899.11 million by 2025 from USD 506.48 million in 2022, at a CAGR of 22.1% from 2020 to 2023. The human microbiome research spending market is expected to reach USD 800.8 million by 2020 from USD 423.3 million in 2015, at a CAGR of 13.6% from 2015 to 2020.
The market is driven by the increasing prevalence of chronic and lifestyle diseases; augmented awareness and acceptance of prebiotics, probiotics, and medical foods; ongoing research activities; and advancements in molecular diagnostic techniques. However, persistent regulatory issues and approval concerns for microbiome-based products may curb the growth of this market. However, government regulation and lack of detailed research may restrain the growth of this market to an extent.
Download the PDF Brochure@
Based on disease, the market is categorized into obesity, diabetes, autoimmune disorders, cancer, acute diarrhea, mental disorders, and other diseases such as cardiovascular diseases, other immune disorders (irritable bowel syndrome), metabolic syndrome (elevated blood lipids, high BP, and liver diseases), other mental disorders (bipolar disorders, schizophrenia, and drug metabolism), and atopic dermatitis. Acute diarrhea is expected to account for the largest share of the market in 2022.
Factors such as rising prevalence of communicable diseases, growing awareness among patients regarding the use of microbiome-based products, and technological advancements will stimulate the growth of this segment in the human microbiome disease market.
The human microbiome research spending market, by technology, is divided into cell culture technology, high-throughput technology, omics technology, and computational tools. The cell culture technology is the most widely-used technology in microbiome research, and is expected to account for the largest share of the human microbiome research spending market in 2016. The large share of this segment can be attributed to its usage in the in vitro model to reproduce in vivo conditions and to study host-microbial community interactions.
Europe is expected to dominate the market with a share of in 2022. It is the prime market for microbiome companies due to the huge awareness and acceptance of microbiome-based products, rising incidences of chronic and lifestyle diseases, and high awareness of pharmacogenomics/personalized medicine in this region. In addition, major local companies have easy access to this market, which makes Europe the largest and most significant market for suppliers.
Get the Sample Pages for More Details@
The key players in the human microbiome market are Enterome Bioscience (France), Yakult Honsha Co., Ltd. (Japan), E. I. Du Pont de Nemours and Company (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome, Inc. (U.S.), MicroBiome Therapeutics LLC (U.S.), Vedanta BioSciences, Inc. (U.S.), Osel, Inc. (U.S.), and Merck & Co, Inc. (U.S.)
Mr. Shelly Singh
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.